Pedro is a cancer biologist and enterpreneur with a long standing interest in the tumour microenvironment (TME), as both a mediator of cancer progression and therapy resistance, and an effective therapeutic target. He obtained his PhD from the University of Cambridge, where he initially developed new 3D models to study angiogenesis in solid tumours. Pedro then moved to the MD Anderson Cancer Center in Houston, Texas, for a postdoctoral fellowship studying spatial interactions between stromal components and immune cell infiltration in solid tumours. His observations made him decide to build innovative solutions to tackle this problem, leading him to return to the UK and co-found Neobe. He has since grown the company and raised £3.5M in equity and non-dilutive funds, enabling the establishment of its engineered bacterial therapeutics platform, with two assets currently in pre-clinical development.